Free Trial
OTCMKTS:CPMV

Mosaic ImmunoEngineering Q4 2025 Earnings Results & Report

Mosaic ImmunoEngineering logo
$0.33 +0.27 (+432.80%)
As of 10/9/2026 12:56 PM Eastern

Mosaic ImmunoEngineering reported Q4 2025 earnings on April 15, 2026. The company reported EPS of -$0.03.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
During Market Hours

Mosaic ImmunoEngineering EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mosaic ImmunoEngineering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Mosaic ImmunoEngineering Q4 2025 Earnings FAQ

Mosaic ImmunoEngineering (OTCMKTS:CPMV) reported earnings of -$0.03 per share for Q4 2025. The report was announced on Wednesday, April 15, 2026.

Mosaic ImmunoEngineering Earnings Headlines

Mosaic ImmunoEngineering Delays Annual 10-K Filing
Mosaic ImmunoEngineering, Inc. (CPMV) - Yahoo Finance
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Mosaic ImmunoEngineering, Inc. (CPMV)
Mosaic Co.
See More Mosaic ImmunoEngineering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mosaic ImmunoEngineering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mosaic ImmunoEngineering and other key companies, straight to your email.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering (OTCMKTS:CPMV), Inc. is a biotechnology company focused on developing immunotherapies designed to stimulate the immune system to recognize and attack disease-related cells. Its work has centered primarily on therapeutic approaches for cancer and potentially other serious diseases.

The company’s activities have included research into multi-antigen immune-response technologies and vaccine-based therapies intended to activate T cells against selected targets. Publicly available information about its current development programs, commercial products, geographic operations and leadership is limited.

View Mosaic ImmunoEngineering Profile